NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brainâs electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Companyâs RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.
äŒæ¥ã³ãŒãNPCE
äŒç€ŸåNeuropace Inc
äžå Žæ¥Apr 22, 2021
æé«çµå¶è²¬ä»»è
ãCEOãBecker (Joel D)
åŸæ¥å¡æ°184
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Apr 22
æ¬ç€Ÿæåšå°455 N. Bernardo Avenue
éœåžMOUNTAIN VIEW
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·94043
é»è©±çªå·16502372700
ãŠã§ããµã€ãhttps://www.neuropace.com/
äŒæ¥ã³ãŒãNPCE
äžå Žæ¥Apr 22, 2021
æé«çµå¶è²¬ä»»è
ãCEOãBecker (Joel D)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã